Prolyl isomerase Pin1 downregulates tumor suppressor RUNX3 in breast cancer

Oncogene

Volumn 32, Issue 12, 2013, Pages 1488-1496

  Nicole Tsang, Y H ^a,b   Wu, X W ^a   Lim, J S ^a   Wee Ong, C ^c,d   Salto Tellez, M ^c,d   Ito, K ^e   Ito, Y ^b,d   Chen, L F ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e NAGASAKI UNIVERSITY   (Japan)

Author keywords

breast cancer; degradation; Pin1; RUNX3; tumor suppressor; ubiquitination

Indexed keywords

PEPTIDYLPROLYL ISOMERASE PIN1; TRANSCRIPTION FACTOR RUNX3;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; UBIQUITINATION;

AMINO ACID MOTIFS; BREAST NEOPLASMS; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 3 SUBUNIT; DOWN-REGULATION; FEMALE; HUMANS; PEPTIDYLPROLYL ISOMERASE; PHOSPHORYLATION; PROTEIN STABILITY; TUMOR SUPPRESSOR PROTEINS; UBIQUITINATION;

MUS;

EID: 84884211458     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.178     Document Type: Article

References (40)

1. Katzenellenbogen BS, Katzenellenbogen JA. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Res 2000; 2: 335-344.
2. Cheskis BJ, Greger JG, Nagpal S, Freedman LP. Signaling by estrogens. J Cell Physiol 2007; 213: 610-617.
3. Lee EY, Muller WJ. Oncogenes and tumor suppressor genes. Cold Spring Harb Perspect Biol 2010; 2: a003236.
4. Huang B, Qu Z, Ong CW, Tsang YH, Xiao G, Shapiro D et al. RUNX3 acts as a tumor suppressor in breast cancer by targeting estrogen receptor alpha. Oncogene 2011; 31: 527-534.
5. Ito Y. Oncogenic potential of the RUNX gene family: 'overview'. Oncogene 2004; 23: 4198-4208.
6. Subramaniam MM, Chan JY, Soong R, Ito K, Ito Y, Yeoh KG et al. RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression. Breast Cancer Res Treat 2009; 113: 113-121.
7. Jiang Y, Tong D, Lou G, Zhang Y, Geng J. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines. Pathobiology 2008; 75: 244-251.
8. Lau QC, Raja E, Salto-Tellez M, Liu Q, Ito K, Inoue M et al. RUNX3 is frequently inactivated by dual mechanisms of protein mislocalization and promoter hypermethylation in breast cancer. Cancer Res 2006; 66: 6512-6520.
9. Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, Salto-Tellez M. Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 2009; 1796: 315-331.
10. Chen LF. Tumor suppressor function of RUNX3 in breast cancer. J Cell Biochem 2012; 113: 1470-1477.
11. Chuang LS, Ito Y. RUNX3 is multifunctional in carcinogenesis of multiple solid tumors. Oncogene 2010; 29: 2605-2615.
12. Hwang KT, Han W, Bae JY, Hwang SE, Shin HJ, Lee JE et al. Downregulation of the RUNX3 gene by promoter hypermethylation and hemizygous deletion in breast cancer. J Korean Med Sci 2007; 22(Suppl): S24-S31.
13. Bae SC, Lee YH. Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation. Gene 2006; 366: 58-66.
14. Bae JS, Jang MK, Hong S, An WG, Choi YH, Kim HD et al. Phosphorylation of NF-kappa B by calmodulin-dependent kinase IV activates anti-apoptotic gene expression. Biochem Biophys Res Commun 2003; 305: 1094-1098.
15. Lu KP, Zhou XZ. The prolyl isomerase PIN1: a pivotal new twist in phosphorylation signalling and disease. Nat Rev Mol Cell Biol 2007; 8: 904-916.
16. Liou YC, Zhou XZ, Lu KP. Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci 2011; 36: 501-514.
17. Wulf G, Ryo A, Liou YC, Lu KP. The prolyl isomerase Pin1 in breast development and cancer. Breast Cancer Res 2003; 5: 76-82.
18. Wulf GM, Ryo A, Wulf GG, Lee SW, Niu T, Petkova V et al. Pin1 is over expressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1. EMBO J 2001; 20: 3459-3472.
19. Liou YC, Ryo A, Huang HK, Lu PJ, Bronson R, Fujimori F et al. Loss of Pin1 function in the mouse causes phenotypes resembling cyclin D1-null phenotypes. Proc Natl Acad Sci USA 2002; 99: 1335-1340.
20. Rajbhandari P, Finn G, Solodin NM, Singarapu KK, Sahu SC, Markley JL et al. Regulation of ERalpha N-terminus conformation and function by peptidyl prolyl isomerase Pin1. Mol Cell Biol 2011; 32: 445-457.
21. Yi P, Wu RC, Sandquist J, Wong J, Tsai SY, Tsai MJ et al. Peptidyl-prolyl isomerase 1 (Pin1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3 (SRC-3/AIB1). Mol Cell Biol 2005; 25: 9687-9699.
22. Rustighi A, Tiberi L, Soldano A, Napoli M, Nuciforo P, Rosato A et al. The prolylisomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. Nat Cell Biol 2009; 11: 133-142.
23. Reineke EL, Lam M, Liu Q, Liu Y, Stanya KJ, Chang KS et al. Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. Mol Cell Biol 2008; 28: 997-1006.
24. Lim JH, Liu Y, Reineke E, Kao HY. The MAPK ERK2 phosphorylates and promotes Pin1-dependent promyelocytic leukemia protein (PML) turnover. J Biol Chem 2011; 286: 44403-44411.
25. Davis FM, Tsao TY, Fowler SK, Rao PN. Monoclonal antibodies to mitotic cells. Proc Natl Acad Sci USA 1983; 80: 2926-2930.
26. Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld JU et al. Sequence-specific and phosphorylation-dependent proline isomerization: a potential mitotic regulatory mechanism. Science 1997; 278: 1957-1960.
27. Lu PJ, Zhou XZ, Liou YC, Noel JP, Lu KP. Critical role of WW domain phosphorylation in regulating phosphoserine binding activity and Pin1 function. J Biol Chem 2002; 277: 2381-2384.
28. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH et al. Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Calpha promoter. J Biol Chem 1999; 274: 31577-31582.
29. Schutkowski M, Bernhardt A, Zhou XZ, Shen M, Reimer U, Rahfeld JU et al. Role of phosphorylation in determining the backbone dynamics of the serine/threonine-proline motif and Pin1 substrate recognition. Biochemistry 1998; 37: 5566-5575.
30. Zhang M, Xie R, Hou W, Wang B, Shen R, Wang X et al. PTHrP prevents chondrocyte premature hypertrophy by inducing cyclin-D1-dependent Runx2 and Runx3 phosphorylation, ubiquitylation and proteasomal degradation. J Cell Sci 2009; 122: 1382-1389.
31. Butt AJ, Caldon CE, McNeil CM, Swarbrick A, Musgrove EA, Sutherland RL. Cell cycle machinery: links with genesis and treatment of breast cancer. Adv Exp Med Biol 2008; 630: 189-205.
32. Jin YH, Jeon EJ, Li QL, Lee YH, Choi JK, Kim WJ et al. Transforming growth factorbeta stimulates p300-dependent RUNX3 acetylation, which inhibits ubiquitination-mediated degradation. J Biol Chem 2004; 279: 29409-29417.
33. Nakano A, Koinuma D, Miyazawa K, Uchida T, Saitoh M, Kawabata M et al. Pin1 down-regulates transforming growth factor-beta (TGF-beta) signaling by inducing degradation of Smad proteins. J Biol Chem 2009; 284: 6109-6115.
34. Huang G, Shigesada K, Ito K, Wee HJ, Yokomizo T, Ito Y. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J 2001; 20: 723-733.
35. Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, Stoller G et al. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell 2000; 6: 873-883.
36. Bao L, Kimzey A, Sauter G, Sowadski JM, Lu KP, Wang DG. Prevalent overexpression of prolyl isomerase Pin1 in human cancers. Am J Pathol 2004; 164: 1727-1737.
37. Wulf G, Finn G, Suizu F, Lu KP. Phosphorylation-specific prolyl isomerization: is there an underlying theme? Nat Cell Biol 2005; 7: 435-441.
38. Tsang YH, Lamb A, Romero-Gallo J, Huang B, Ito K, Peek Jr RM et al. Helicobacter pylori CagA targets gastric tumor suppressor RUNX3 for proteasome-mediated degradation. Oncogene 2010; 29: 5643-5650.
39. Zhang DH, Salto-Tellez M, Chiu LL, Shen L, Koay ES. Tissue microarray study for classification of breast tumors. Life Sci 2003; 73: 3189-3199.
40. Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kB. EMBO J 2002; 21: 6539-6548.